Images List Premium Download Classic

HLA

HLA-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods and compositions for vaccinating a subject for a sexually transmitted pathogen
The Regents Of The University Of California
September 07, 2017 - N°20170252424

Purified chlamydia major outer membrane protein (momp) has been observed to induce protection against genital and respiratory challenge in mice. Momp contains variable domains that are highly immunogenic and elicit cross-serovar neutralizing monoclonal and polyclonal antibodies and t cell responses in animal and human models. Examples herein provide a method for vaccinating a subject against chlamydia using a composition that ...
Tomm34 peptides and vaccines including the same
Oncotherapy Science, Inc.
July 13, 2017 - N°20170198010

The present invention provides isolated peptides or the fragments derived from seq id no: 42, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these ...
Agent for prevention and treatment of chlamydia infection
Kabushiki Kaisha Yakult Honsha
July 13, 2017 - N°20170196917

An agent for the prevention and treatment of chlamydia infection containing lactobacillus casei as an active ingredient which is an agent for the prevention and treatment of chlamydia infection that is highly safe and that can be administered over an extended period of time.
HLA Patent Pack
Download + patent application PDFs
HLA Patent Applications
Download + HLA-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of HLA-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of detecting alloantibodies using hla and non-hla antigens
One Lambda, Inc.
March 23, 2017 - N°20170082619

Described herein are materials and methods for detecting alloantibodies using both hla and non-hla antigens in a single assay.
Compositions and methods for immunodominant antigens
Immport Therapeutics, Inc.
March 23, 2017 - N°20170081659

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (burkholderia pseudomallei, borrelia burgdorferi, brucella melitensis, chlamydia muridarum, coxiella burnetii, francisella tularensis, human herpes virus 1 and 2, mycobacterium tuberculosis, plasmodium falciparum, and vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities ...
Methods and compositions for treatment of chlamydial infection and related diseases and disorders
Wake Forest University Health Sciences
March 09, 2017 - N°20170067059

The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.
HLA Patent Pack
Download + patent application PDFs
HLA Patent Applications
Download + HLA-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of HLA-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Chlamydia vaccine
Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services
January 26, 2017 - N°20170021007

Compositions and methods for the treatment of chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a chlamydia antigen and dna sequences encoding such polypeptides. Pharmaceutical compositions, vaccines and diagnostic kits are also disclosed.
Hjurp peptides and vaccines including the same
Oncotherapy Science, Inc.
December 22, 2016 - N°20160368958

Isolated peptides derived from seq id no: 50 and fragments thereof that bind to an hla antigen and induce cytotoxic t lymphocytes (ctl) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines are described herein. The inventive peptides encompasses both the above mentioned amino acid sequences and modified versions thereof, in which one, two, ...
Immunogenic compositions
Sanofi Pasteur, S.a.
December 22, 2016 - N°20160367655

The present invention provides compositions comprising a chlamydial major outer membrane protein (referenced herein as “momp”), from at least one chlamydial serovar and an adjuvant, characterized in that the adjuvant comprises the product e6020 having cas number 287180-63-6. The composition may further comprise at least one carrier system (e. G., emulsion, mineral particle). The momp ...
Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene
Becton, Dickinson And Company
December 01, 2016 - N°20160348156

A region of the chlamydia trachomatis pmpa gene has been identified which is useful for performing amplification assays to determine specifically whether c. Trachomatis is present in the sample being tested. Oligonucleotides useful for detecting this gene by performing the polymerase chain reaction (pcr) are disclosed. The disclosed oligonucleotides can be used in an assay which is specific for multiple ...
Type iii secretion injectisome proteins for treatment and prevention of chlamydial infections
Mcmaster University
December 01, 2016 - N°20160346375

Cpn0803, copb (cpn0809) and copd (cpn0808) proteins and homologues thereof are shown to induce an immune response that is protective against a live challenge with chlamydia. Methods and uses of cpn0803 or fragments or epitopes thereof alone or together with copb and/or copd or fragments or epitopes thereof for treating or preventing chlamydial infection in a subject in need ...
Neil3 peptides and vaccines including the same
Oncotherapy Science, Inc.
November 24, 2016 - N°20160340398

The present invention provides isolated peptides or the fragments derived from seq id no: 45, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides ...
HLA Patent Pack
Download + patent application PDFs
HLA Patent Applications
Download + HLA-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of HLA-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Nucleic acid probe with single fluorophore label bound to internal cytosine for use in loop ...
Mast Group Limited
September 22, 2016 - N°20160273029

The disclosure relates to novel probes for use in lamp detection methods. The probes contain a single fluorophore label bound to an internal cytosine residue of the probe. The probes are particularly useful in the detection of chlamydia and gonorrhea infections in a patient.
Methods of detecting chlamydia and gonorrhea and of screening for infection/inflammation based on genomic ...
Cepheid
September 08, 2016 - N°20160257998

Compositions and methods for detecting chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) are provided. The present invention also provides methods and compositions for screening for infection/inflammation based on genomic copy number. Described herein is a method that entails assaying a sample obtained from the urogenital tract of the mammal for an indicator of genomic copy number, wherein a genomic ...
Methods of detecting antibodies specific for denatured hla antigens
One Lambda, Inc.
August 04, 2016 - N°20160223564

The invention is directed to methods of screening for hla antibodies comprising detecting antibodies specific for native hla antigens and denatured hla antigens. The invention also provides for methods of removing antibodies specific for denatured hla antigens or antibodies specific for native hla antigens from a serum sample. In addition, the invention also provides for method of predicting whether a ...
Compositions and methods for providing hematopoietic function
Fred Hutchinson Cancer Research Center
July 14, 2016 - N°20160199418

The present invention relates to methods and compositions for providing hematopoietic function to human patients in need thereof, by selecting a pool of expanded human cord blood stem/progenitor cell samples for administration to the patient, wherein the samples in the pool collectively do not mismatch the patient at more than 2 of the hla antigens or alleles typed in the ...
Chlamydia antigens
Glaxosmithkline Biologicals Sa
June 09, 2016 - N°20160158337

The invention provides chlamydia antigens for use in the treatment, prevention and/or diagnosis of chlamydia infection. In particular, the invention provides antigens ct733, ct153, ct601, ct279, ct443, ct372, ct456, ct381, ct255, ct341, ct716, ct745, ct387, ct812, ct869, ct166, ct175, ct163, ct214, ct721, ct127, ct043, ct823 and/or ct600 from c. Trachomatis for the treatment, prevention or diagnosis of chlamydia ...
Compositions for and methods of identifying antigens
President And Fellows Of Harvard College
March 31, 2016 - N°20160090589

Replicable libraries having discrete members in defined locations for screening for antigens to a pathogenic organism are provided. Also provided are methods for using such libraries as well as a specific antigen, ct788, which induces t-cell activation during a chlamydia infection.
Omv vaccines
Novartis Ag
March 10, 2016 - N°20160067327

The invention is in the field of outer membrane vesicles (omv) and their uses. More particularly the present invention provides omv obtained from a bacterium being an ompa mutant and/or a mutant in one or more components of the tolpal complex and presenting a heterologous antigen on its surface. The heterologous antigen is selected from the group consisting of ...
Loading